Compare Amphastar Pharmaceuticals Inc (AMPH) vs Freeport-McMoRan Inc (FCX) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

FCX trades at $61.52, up 1.69% on the day, with a bearish technical signal but strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $0.60. Revenue growth is steady, and profitability metrics like a 10.34% net income margin and 14.7% ROE reflect operational strength. Recent news highlights FCX's role in the copper market, driven by AI and energy transition demand.

The outlook is positive due to robust copper demand and expansion projects, but risks include commodity price volatility and high debt. Analysts are bullish with a $73.35 consensus price target, implying 19% upside. Investors should weigh strong cash flows and dividend payments against cyclical industry exposure and macroeconomic headwinds.